Market news

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Viking Therapeutics' VK2735 obesity trial shows strong weight loss and better tolerability. Read the latest analysis on the VKTX stock here.

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

The company continues to make good progress with its key obesity treatment drug, VK2735.

Viking Therapeutics has ridden a powerful share price run and a wave of enthusiasm around its weight loss pipeline. This now puts a spotlight on a quieter question. At today’s level, the issue is whether the stock price lines up with the biopharma group’s book value when set against the industry average. Over the past 5 years, Viking Therapeutics has delivered a very large share price gain. This raises the stakes for whether current investors are paying a level that its balance sheet can...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $36.75, moving 11.76% from the previous trading session.

It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.

A Viking Therapeutics announcement about an equity and debt offering fuels a reaction in the market.

Viking Therapeutics (VKTX) shares are down about 12% this morning after the company priced a $500 million raise. Two days ago, when the stock soared on its maintenance study results, I wrote that “if management needs to dilute shareholders with a follow-on equity offering, I expect plenty of takers.

Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.

Viking Therapeutics priced an upsized financing deal at a 16% discount from the stock’s closing price on Wednesday.

U.S. futures fell as Stitch Fix plunged 18% on weak FY27 guidance; MGM, Viking Therapeutics and other stocks also declined premarket.

Stock market movers today: futures dip amid U.S.-Iran tensions as Everpure jumps on outlook while SFIX, MGM, VKTX & TRU slide.

Retail traders floated Novo Nordisk, AbbVie and Eli Lilly as possible buyers, while others saw the offering as a sign Viking may go it alone.

The San Diego biotech said it intends to offer $200 million of common stock and $200 million of convertible senior notes due 2032, subject to market conditions.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $41.65, representing a +1.96% change from its previous close.

Viking Therapeutics shares are moving lower in extended trading Wednesday after the company announced a pair of proposed public offerings.

Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.

Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other conditions, $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in separate public offerings registered under the Securities Act of 1933, as amended. Viking also expects to grant the und

Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735. Click for more.

Jaguar Health and Viking Therapeutics are both sinking Wednesday morning, but the forces behind each drop point in completely different directions, and the broader biotech sector is barely flinching.

The stock is in a precarious position but offers some promise.

Key Stats for Viking Therapeutics StockPrice change for Viking Therapeutics stock Today: 36%$VKTX Stock Price as of Sep. 22: $4152-Week High: $43$VKTX Stock Price Target: $92What Happened?Viking Therapeutics (VKTX) stock jumped more than 35% on Tuesday after the company released new data on its obesity drug, VK2735.

Viking Therapeutics (VKTX) is back in focus after the company reported positive top-line data from its VK2735-102 maintenance trial and scheduled a special call to walk through the obesity drug findings with investors. The special call and VK2735 update arrive after a sharp move in Viking Therapeutics’ shares, with a 1-day share price return of 35.67% and a 7-day share price return of 36.39%, while the 1-year total shareholder return of 63.60% and very large 5-year total shareholder return...

2026-09-22. The following slide deck was published by Viking Therapeutics, Inc.

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Research has shown the adherence rates of patients on GLP-1 therapies can fall as low as 27% after one year.

JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.

Viking Therapeutics Inc. (NASDAQ:VKTX) soared by a whopping 35.67 percent on Tuesday to close at $40.85 apiece—just $2 shy of its 52-week high—after reporting stellar results from its weight loss drug candidate, VK2735. After 21 weeks of clinical trial, the company said that enrolled patients who took VK2735 successfully lost 16 to 19 percent of […]

The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.

Viking stock catapulted Tuesday on "stellar" test results for its weight-loss shot, sending Novo down.

Shares of Viking Therapeutics (VKTX) are soaring 36% today on impressive new results in an early-stage maintenance study of VK2735, its dual GLP-1 and GIP agonist. What exactly happenedViking’s maintenance study read out today, and the headline numbers are eye-popping: 22% placebo-adjusted weight loss at week 33 (weekly dosing)Up to 97%(!) of weight loss from the weekly phase retained after moving to biweekly dosing for three monthsUp to 90% of weight loss retained after moving to monthly dosing